MARKER THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
MARKER THERAPEUTICS, INC. (MRKR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $35.66 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-18
- MARKER THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2020-03-31 was $7.26.
- MARKER THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.00.
- MARKER THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $35.66, a 15.58% decline from fiscal 2024.
- MARKER THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $42.24.
- MARKER THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $36.78, a 2.39% increase from fiscal 2021.
- MARKER THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $35.92.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $35.66 10-K · filed 2026-03-18 | ||||
| 2024-12-31 | $42.24 10-K · filed 2026-03-18 | ||||
| 2022-12-31 | $36.78 10-K · filed 2023-03-22 | ||||
| 2021-12-31 | $35.92 10-K · filed 2023-03-22 | $3.59 10-K · filed 2022-03-17 | |||
| 2020-09-30 | $9.13 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | $9.13 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | $7.26 10-Q · filed 2020-05-11 | ||||
| 2016-12-31 | $228.00 10-K · filed 2017-03-14 | ||||
| 2016-09-30 | $228.00 10-Q · filed 2016-11-04 | ||||
| 2015-12-31 | $0.00 10-K · filed 2017-03-14 | ||||
| 2015-09-30 | $0.25 10-Q/A · filed 2016-04-14 | ||||
| 2015-06-30 | $0.50 10-Q/A · filed 2016-04-14 | ||||
| 2015-03-31 | $0.00 10-Q/A · filed 2016-04-14 | ||||
| 2012-06-30 | $0.00 10-Q/A · filed 2012-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |